Pharma Mar : Liquidity contracts and specialists

January 08, 2019 at 05:54 pm

National Securities Market Commission Markets Directorate General

C/ Edison núm. 4

28006 Madrid

Colmenar Viejo (Madrid), January 8, 2019

Pursuant to article 228 of the restated text of the Securities Market Law, we hereby inform you of the following SIGNIFICANT EVENT:

Quarterly operations liquidity agreement:

On June 4, 2018, Pharma Mar, S.A. entered into a liquidity agreement with JB CAPITAL MARKETS, SOCIEDAD DE VALORES, S.A.U. in order to promote the liquidity of the transactions and the regularity of the listing of its shares, which entered into force on June 5, 2018, and was notified to the market by means of significant event dated June 4, 2018 (with registration number 266.399).

In compliance with the provisions of section 2.b) of Rule Fourth of Circular 1/2017, of 26 April, of the National Securities Market Commission, on liquidity agreements, below are detailed the operations carried out under the aforementioned liquidity agreement corresponding to the last quarter of Year 2018 (from October 1, 2018 to December 31, 2018).

AverageTransactions

SharesAmount (€)Price

Initial Amount as per Agreement

(05/06/2018) 407.319600.000,00
Initial Amount Period (01/10/2018) 466.086524.409,71

Purchases Sales

1.152.746-918.622

-1.371.719,56 1,189958204

1.113.990,17

1,212675257

Expenses 1.928,63

Final amount

700.210264.751,69

Below is a detail of the transactions carried out on treasury stock during the period covered by this communication (01/10/2018 to 31/12/2018)

Buy/SellsDateNº SharesBlockNº operations

Average Price (€)Cash (€)Shares as of the relevant date

Effective amount

Beginning balance

Disposals Acquisitions Disposals Acquisitions Disposals Acquisitions Disposals Acquisitions Disposals Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Acquisitions Disposals Acquisitions Disposals Acquisitions Disposals Acquisitions Disposals Acquisitions Disposals Disposals Disposals Disposals Disposals Acquisitions Disposals Acquisitions Disposals Acquisitions Disposals

01 / 10 / 2018 -23.000

02 / 10 / 2018

03 / 10 / 2018

04 / 10 / 2018

05 / 10 / 2018

08 / 10 / 2018

09 / 10 / 2018

10 / 10 / 2018

11 / 10 / 2018

12 / 10 / 2018

15 / 10 / 2018

16 / 10 / 2018

17 / 10 / 2018

18 / 10 / 2018

19 / 10 / 2018

22 / 10 / 2018

23 / 10 / 2018

24 / 10 / 2018

25 / 10 / 2018

6.980

-6.000

14.208

-5.000

11.196

-518

17.108

-2.000

24.148

50.328

15.000

8.996

21.940

10.000

77.466

20.200

2.000

14.788

19.417

14.260

-8.267

25 / 10 / 2018 -15.000

26 / 10 / 2018

26 / 10 / 2018 -12.000

29 / 10 / 2018

29 / 10 / 2018 -25.000

30 / 10 / 2018

17.000 30.185 11.840 16.840 -1.965

31 / 10 / 2018 -80.000

01 / 11 / 2018 -45.000

02 / 11 / 2018 -133.000

05 / 11 / 2018 -15.000

06 / 11 / 2018

07 / 11 / 2018

07 / 11 / 2018 -10.000

08 / 11 / 2018

25.000 -1.755 24.600 1.000

08 / 11 / 2018 -40.000

524.409,71

466.086

N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

1,6

35.872

443.086 560.281,71

1,6

-11.177

450.066 549.104,29

1,6

9.704

444.066 558.808,29

1,6

-22.190

458.274 536.618,26

1,6

7.850

453.274 544.468,26

1,5

-17.334

464.470 527.134,03

1,6

811

463.952 527.944,70

1,5

-26.095

481.060 501.850,12

1,5

3.060

479.060 504.910,12

1,5

-36.449

503.208 468.460,77

1,5

-75.076

553.536 393.384,82

1,4

-21.748

568.536 371.636,82

1,4

-12.213

577.532 359.424,20

1,3

-29.029

599.472 330.395,46
7
1,3
-12.794
609.472 317.601,46

1,2

-91.581

686.938 226.019,97

1,2

-23.783

707.138 202.236,77

1,1

-2.258

709.138 199.978,77

1,1

-15.850

723.926 184.128,52

1,0

-20.027

743.343 164.101,91

0,9

-13.535

757.603 150.567,12

1,0

8.102

749.336 158.668,78

1,0

-16.180

766.336 142.488,78

1,0

14.700

751.336 157.188,78

0,9

-27.135

781.521 130.053,96

0,9

11.376

769.521 141.429,96

1,0

-11.420

781.361 130.009,53

1,0

24.814

756.361 154.823,53

1,0

-16.363

773.201 138.460,83

1,0

1.996

771.236 140.457,27

1,1

84.163

691.236 224.620,27

1,2

51.975

646.236 276.595,27

1,3

176.451

513.236 453.046,27

1,4

21.000

498.236 474.046,27

1,3

-33.610

523.236 440.436,27

1,4

2.401

521.481 442.837,11

1,4

-33.394

546.081 409.442,71

1,4

13.520

536.081 422.962,71
1
1,3
-1.300
537.081 421.662,71

1,4

54.800

497.081 476.462,71

Acquisitions	09 / 11 / 2018	40.700
Acquisitions	12 / 11 / 2018	22.894
Acquisitions	13 / 11 / 2018	2.000
Acquisitions	14 / 11 / 2018	40.470
Acquisitions	15 / 11 / 2018	11.170
Acquisitions	16 / 11 / 2018	30.000
Disposals
Acquisitions
Acquisitions
Acquisitions
Acquisitions
Disposals
Disposals
Disposals
Acquisitions
Disposals
Acquisitions
Disposals
Acquisitions
Disposals
Acquisitions
Disposals
Disposals
Disposals
Acquisitions
Acquisitions
Disposals
Acquisitions
Disposals
Acquisitions
Disposals
Disposals
Acquisitions
Disposals
Acquisitions
Acquisitions
Acquisitions
Acquisitions
Acquisitions
Acquisitions
Disposals
Acquisitions
Disposals

19 / 11 / 2018 -27.054


20 / 11 / 2018	27.000
21 / 11 / 2018	30.000
22 / 11 / 2018	17.007
23 / 11 / 2018	5.000
23 / 11 / 2018	-943

26 / 11 / 2018 -53.372

27 / 11 / 2018 -53.234

28 / 11 / 2018 -21.000


29 / 11 / 2018	15.000
29 / 11 / 2018	-5.000
30 / 11 / 2018	16.600
30 / 11 / 2018	-7.184
03 / 12 / 2018	20.000
03 / 12 / 2018	-9.330

04 / 12 / 2018 -20.000

05 / 12 / 2018 -20.000


06 / 12 / 2018	65.909
07 / 12 / 2018	10.000

07 / 12 / 2018 -40.000

11 / 12 / 2018 -80.000

12 / 12 / 2018 -60.000

13 / 12 / 2018 -10.000

28 / 11 / 2018

10 / 12 / 2018 -10.000

21 / 12 / 2018 -43.000


14 / 12 / 2018	28.352
17 / 12 / 2018	16.830
18 / 12 / 2018	25.352
19 / 12 / 2018	54.188
20 / 12 / 2018	2.000
21 / 12 / 2018	4.000

N	18	1,3	-53.269	537.781 423.193,61
N	5	1,2	-28.014	560.675 395.180,03
N	1	1,2	-2.392	562.675 392.788,03
N	27	1,1	-45.750	603.145 347.037,73
N	12	1,0	-11.612	614.315 335.425,72
N	9	1,1	-31.540	644.315 303.885,72
N	19	1,1	29.327	617.261 333.212,26
N	16	1,0	-27.544	644.261 305.668,26
N	11	1,0	-30.620	674.261 275.048,26
N	7	1,0	-17.824	691.268 257.223,94
N	2	1,0	-5.210	696.268 252.013,94
N	1	1,1	1.000	695.325 253.013,52
N	17	1,1	57.135	641.953 310.148,30
N	15	1,1	59.892	588.719 370.040,06
N	10	1,1	-33.930	618.719 336.110,06
N	5	1,2	24.440	597.719 360.550,06
N	3	1,1	-16.870	612.719 343.680,06
N	2	1,1	5.720	607.719 349.400,06
N	5	1,1	-18.138	624.319 331.261,66
N	3	1,1	8.046	617.135 339.307,74
N	5	1,1	-21.715	637.135 317.592,74
N	5	1,2	10.767	627.805 328.359,56
N	8	1,2	23.205	607.805 351.564,56
N	9	1,2	23.970	587.805 375.534,56
N	28	1,2	-77.000	653.714 298.534,21
N	2	1,2	-11.500	663.714 287.034,21
N	24	1,2	47.000	623.714 334.034,21
N	4	1,2	-16.228	637.714 317.806,21
N	4	1,2	11.800	627.714 329.606,21
N	6	1,3	-25.280	647.714 304.326,21
N	31	1,3	104.255	567.714 408.581,21
N	10	1,3	80.300	507.714 488.881,21
N	14	1,3	-28.287	529.761 460.593,98
N	5	1,3	13.100	519.761 473.693,98
N	31	1,3	-35.522	548.113 438.172,32
N	11	1,2	-20.973	564.943 417.199,33
N	17	1,2	-30.388	590.295 386.811,77
N	39	1,2	-63.263	644.483 323.548,31
N	2	1,1	-2.286	646.483 321.262,31
N	3	1,1	-4.592	650.483 316.670,31
N	20	1,2	50.278	607.483 366.948,31
N	8	1,2	-10.192	616.187 356.755,93
24 / 12 / 2018 -20.000	N	2	1,2	23.690	596.187 380.445,93

10 / 12 / 2018

11 / 12 / 2018

13 / 12 / 2018

24 / 12 / 2018

30.000

14.000

20.000

22.047

8.704

Acquisitions
Disposals
Acquisitions	28 / 12 / 2018	42.105
Disposals	28 / 12 / 2018	-3.000
Acquisitions	31 / 12 / 2018	51.018

N	11	1,1	-29.634	622.087 350.811,73
27 / 12 / 2018 -12.000	N	11	1,2	13.956	610.087 364.767,73
N	32	1,1	-46.537	652.192 318.230,99
N	2	1,2	3.516	649.192 321.746,99
N	34	1,1	-55.067	700.210 266.680,32

27 / 12 / 2018

25.900

Attachments

Original document
Permalink

Disclaimer

Pharma Mar SA published this content on 08 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 08 January 2019 17:53:05 UTC

	1st Jan change	Capi.
PHARMA MAR, S.A.	-18.74%	637M
CSL LIMITED	+4.57%	97.7B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.43B
BIOGEN INC.	-12.80%	32.85B
UCB	+80.99%	29.33B
BIOMARIN PHARMACEUTICAL INC.	-15.53%	15.47B
INCYTE CORPORATION	-8.70%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.51B
ALTEOGEN INC.	+183.25%	10.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.41%	8.97B

1st Jan change

Capi.

PHARMA MAR, S.A.

-18.74%

637M

CSL LIMITED

+4.57%

97.7B

SAMSUNG BIOLOGICS CO.,LTD.

+5.66%

41.43B

BIOGEN INC.

-12.80%

32.85B

UCB

+80.99%

29.33B

BIOMARIN PHARMACEUTICAL INC.

-15.53%

15.47B

INCYTE CORPORATION

-8.70%

12.89B

BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.

-12.22%

11.51B

ALTEOGEN INC.

+183.25%

10.74B

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

-55.41%

8.97B

Market Closed - BME Other stock markets 16:35:27 05/07/2024 BST			5-day change	1st Jan Change
33.38 ^EUR	+1.46%		+4.90%	-18.74%

06-04	Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung Cancer	CI
04-23	Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung Cancer	06-04	CI
Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024	02-29
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication	12-18	MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12-12	MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	12-04	MT
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru	11-07	MT
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal	11-06	MT
Transcript : Pharma Mar, S.A., Q3 2023 Earnings Call, Oct 27, 2023	27/10/23
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Pharma Mar, S.A. commences an Equity Buyback Plan, under the authorization approved on May 31, 2023.	05/09/23	CI
Transcript : Pharma Mar, S.A., H1 2023 Earnings Call, Jul 28, 2023	28/07/23
Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	27/07/23	CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment	11/07/23	MT
Monetary optimism and Inditex drive the Ibex-35 to one-and-a-half month highs	07/06/23	RE
The Ibex rises cautiously as it waits for central banks to make their moves	06/06/23	RE
Pharma Mar Recruits First Patient for Solid Tumor Treatment Trial	04/05/23	MT
Transcript : Pharma Mar, S.A., Q1 2023 Earnings Call, Apr 27, 2023	27/04/23
Ibex-35 gives ground as it digests results, awaiting central banks	27/04/23	RE
Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Transcript : Pharma Mar, S.A., 2022 Earnings Call, Mar 01, 2023	01/03/23
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Pharma Mar Wins Conditional Approval For Lung Cancer Drug In Israel	31/01/23	MT
Spain's Pharma Mar Wins Approval for Lung Cancer Drug in Mexico	24/01/23	MT

Pharma Mar, S.A.

Equities

PHM

ES0169501022

Pharmaceuticals

Pharma Mar : Liquidity contracts and specialists

Latest news about Pharma Mar, S.A.

Chart Pharma Mar, S.A.

Company Profile

Income Statement Evolution

Ratings for Pharma Mar, S.A.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals